The mutation frequency of KRAS in lung cancer patients shows a metastatic site-dependent variation, and approximately 30% of all pan-KRAS-mutant lung cancers progress to bone metastasis.5,6 Mutation of KRAS is a predictive factor for treatment efficacy, as well as a prognostic factor for disease progression. The gene discussed is KRAS; the disease is lung carcinoma.